Clinical Outcomes of Autologous Induced Pluripotent Stem Cell-Derived Therapy in Patients with Chronic Degenerative Diseases: A Prospective Multicenter Study
Advanced Journal of Biomedicine & Medicine · 2026
DOI: 10.18081/ajbm.2026.2.176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Journal of Biomedicine & Medicine, 2026. Verfasst von Rajesh Kumar Sharma und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Induced pluripotent stem cells (iPSCs) offer a patient-specific platform for tissue regeneration, disease modeling, and personalized therapy. However, clinical evidence regarding the feasibility, safety, and therapeutic effectiveness of autologous iPSC-derived interventions remains limited, particularly within the Indian healthcare setting. This study evaluated the clinical translation of autologous iPSC-based regenerative therapy in patients with chronic degenerative diseases.
Methods
This prospective, multicenter observational study enrolled 102 adults treated at three tertiary care centers in India. Peripheral blood mononuclear cells were reprogrammed using a non-integrating Sendai viral vector and differentiated into disease-specific therapeutic progenitor cells under xeno-free, Good Manufacturing Practice-compatible conditions. Participants received 5 × 10⁶ to 2 × 10⁷ viable autologous cells through disease-appropriate administration routes. Clinical function, quality of life, inflammatory biomarkers, imaging findings, and adverse events were assessed at baseline and at 1, 3, 6, and 12 months. Longitudinal outcomes were analyzed using repeated-measures analysis of variance, and predictors of favorable response were evaluated by multivariable logistic regression.
Results
Clinically suitable iPSC lines were successfully generated for 98 of 102 participants (96.1%). Mean functional scores improved from 46.8 ± 8.9 at baseline to 71.4 ± 10.6 at 12 months, while quality-of-life scores increased from 52.3 ± 11.7 to 78.6 ± 9.8 (both P < .001). Significant reductions were observed in C-reactive protein, interleukin-6, and tumor necrosis factor-α concentrations. Marked radiological improvement occurred in 72 participants (70.6%), and the overall favorable clinical response rate was 80.4%. Fifteen participants experienced mild or moderate adverse events. No treatment-related death, tumor formation, severe immune reaction, or opportunistic infection was identified during follow-up. Younger age, shorter disease duration, and higher cell viability independently predicted a favorable response.
Conclusion
Autologous iPSC-derived therapy was feasible and associated with improved functional, biochemical, and radiological outcomes over 12 months, with an acceptable short-term safety profile. Larger randomized, disease-specific trials with extended surveillance are required before routine clinical implementation. Keywords: Induced pluripotent stem cells; Regenerative medicine; Autologous cell therapy; Clinical translation; Inflammatory biomarkers.
Zitieren
APA
Sharma, R. K., Menon, P., & Patel, A. (2026). Clinical Outcomes of Autologous Induced Pluripotent Stem Cell-Derived Therapy in Patients with Chronic Degenerative Diseases: A Prospective Multicenter Study. Advanced Journal of Biomedicine & Medicine. https://doi.org/10.18081/ajbm.2026.2.176
Vancouver
Sharma RK, Menon P, Patel A. Clinical Outcomes of Autologous Induced Pluripotent Stem Cell-Derived Therapy in Patients with Chronic Degenerative Diseases: A Prospective Multicenter Study. Advanced Journal of Biomedicine & Medicine. 2026. doi:10.18081/ajbm.2026.2.176
BibTeX
@article{Sharma2026,
author = {Sharma, Rajesh Kumar and Menon, Priya and Patel, Arjun},
title = {Clinical Outcomes of Autologous Induced Pluripotent Stem Cell-Derived Therapy in Patients with Chronic Degenerative Diseases: A Prospective Multicenter Study},
journal = {Advanced Journal of Biomedicine & Medicine},
year = {2026},
doi = {10.18081/ajbm.2026.2.176}
}
EUVIMED